Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NewcelX ( (NCEL) ) has issued an update.
NewCelX Ltd., previously known as NLS Pharmaceutics Ltd., has undergone a significant change in its accounting firm as part of its merger with Kadimastem Ltd. On November 20, 2025, Ernst & Young (EY) was appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This decision follows the dismissal of CBIZ CPAs, who had replaced Marcum LLP earlier in September 2025. The transition to EY is a strategic move post-merger, aligning the company’s accounting practices with its new operational structure.
More about NewcelX
Average Trading Volume: 182,857
Technical Sentiment Signal: Sell
Current Market Cap: $1.41M
Learn more about NCEL stock on TipRanks’ Stock Analysis page.